Medicalgorithmics (LTS:0QR8) Research & Development: zł0.00 Mil (TTM As of Mar. 2026)


LTS:0QR8 Medicalgorithmics SA LTS:0QR8
71 GF Score
Price zł33.07
GF Value zł31.62
! 4 Warning Signs
View Full Analysis

What is Medicalgorithmics Research & Development?

Medicalgorithmics LTS:0QR8 71 Research & Development is zł0.00 Mil as of Mar. 2026. GuruFocus rates LTS:0QR8 with a GF Score™ of 71/100 and a GF Value™ of zł31.62. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Medicalgorithmics's Research & Development for the three months ended in Mar. 2026 was zł0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was zł0.00 Mil.

Medicalgorithmics  (LTS:0QR8) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Medicalgorithmics Research & Development Related Terms

Medicalgorithmics Research & Development Historical Data

* Premium members only.

The historical data trend for Medicalgorithmics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicalgorithmics Research & Development Chart

Medicalgorithmics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Medicalgorithmics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0QR8
71GF Score
Medicalgorithmics SA LTS:0QR8
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicalgorithmics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of zł0.00 Mil mean?
Medicalgorithmics (LTS:0QR8) has a Research & Development of zł0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Medicalgorithmics and its competitors.
Is Medicalgorithmics' Research & Development too high?
Medicalgorithmics' current Research & Development is zł0.00 Mil. Overall, Medicalgorithmics has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Medicalgorithmics' Research & Development compare to ABT and SYK?
Medicalgorithmics' Research & Development of zł0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Medicalgorithmics and its competitors. Medicalgorithmics's current Research & Development is zł0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicalgorithmics stock overvalued right now?
Medicalgorithmics (LTS:0QR8) has a current Research & Development of zł0.00 Mil. The stock's GF Value™ is zł31.62, compared to a current price of zł33.07 — trading 4.6% above its estimated fair value. The current Research & Development is zł0.00 Mil. Medicalgorithmics' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Medicalgorithmics (LTS:0QR8), the current Research & Development is zł0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medicalgorithmics (LTS:0QR8) Overvalued in 2026?

Based on GuruFocus' analysis, Medicalgorithmics stock appears to be overvalued. The current stock price of zł33.07 is trading 4.6% above its estimated GF Value™ of zł31.62.

Key valuation signals for LTS:0QR8:

  • Research & Development: zł0.00 Mil
  • GF Value™: zł31.62 vs. price of zł33.07 (4.6% above fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the LTS:0QR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medicalgorithmics Business Description

Other Exchanges MDG:Poland
Address Al Jerozolimskie 81, 19 Floor, Central Tower Building, Warsaw, POL, 02-001
Medicalgorithmics SA is a medical technology company. It is engaged in the development of Digital Signal Processing (DSP) algorithms development and software and hardware electronics design for medical applications. The company specializes in providing advance technological solutions in the field of cardiac diagnostics, with a particular focus on ECG signal analysis. The group concentrates on the production and development of its flagship product Pocket ECG - a system for remote monitoring of cardiac arrhythmias. The offered solutions include algorithms and diagnostic systems used in remote heart monitoring. The company operates in Poland, the USA, and other, with majority of revenue from the USA.
71GF Score

Get the complete analysis for LTS:0QR8

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł33.07
Price
zł31.62
GF Value